Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Educational Tools for Possible Drug-Induced ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Management of Patients Who Develop ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Changes in Treatment Goals due to Drug Induced ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Risk of ILD as a Class Effect and Identifying ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Risks for Developing ILD in Gastrointestinal Cancer Studies
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Role of Antibody Drug Conjugates and Personal Experience
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Patient Management and Educational Tools for ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Identifying Drug-Induced ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Rate of ILD and Monitoring Parameters
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Personal Experience with Drug-Induced ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Potential Risk of Drug-Induced Interstitial Lung Disease
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Patient Management upon Developing ILD and Education
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Patient Factors for Developing ILD and Personal Experience
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Managing Patient Symptoms and Clinician Education
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
CDK 4/6 Inhibitors and Identifying ILD in Patients
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Rate and Class Effect of ILD with Antibody Drug Conjugates
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Use of Antibody Drug Conjugates and Potential for ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Changes in Cancer Treatment and Management of ILD
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Risks for Developing ILD and Personal Experience
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Antibody Drug Conjugates and Interstitial Lung Disease Risk
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5